Stock Taper
EARNINGS CALL ARCHIVE 1 CALL ON FILE
DNLI — Denali Therapeutics Inc.
NASDAQ
FULL STOCK PAGE →

Q2 2026 Earnings Call Summary

AUG 6, 2026
REVENUE
$3.6M
NET MARGIN
-3539.2%
EPS
-$0.68 +1.4%
FREE CASH FLOW
-$97.8M +26.8%

No summary has been written for this call yet.